Back to search

Article

Early combination with remdesivir, nirmatrelvir/ritonavir and sotrovimab for the treatment of COVID-19 in immunocompromised hosts

2023-09-08

Abstract excerpt

<h4>Background</h4> Immunocompromised patients with COVID-19 have higher morbidity and mortality than general population. Some authors have successfully used antiviral combination, but never in the early phase of the infection. <h4>Methods</h4> Retrospective cohort study to describe efficacy and safety of the combination of 2 antivirals, with or without a mAb, both in early (within 10 days from symptoms) and in la...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
999fe7b3-f3e5-55fd-9dc8-2a1f6fd7d9f0
DOI
10.1101/2023.09.07.23295202
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Early combination with remdesivir, nirmatrelvir/ritonavir and sotrovimab for the treatment of COVID-19 in immunocompromised hostsDOI 10.1101/2023.09.07.23295202
Select a neighboring publication to make it the new centre.